Shareholders to Vote on Highly Dilutive Equity Plan Amidst Going Concern Warning

summarizeSummary

Inmune Bio, Inc. filed its definitive proxy statement, seeking shareholder approval for a new equity incentive plan that could significantly dilute existing shareholders, against a backdrop of a 'going concern' warning from its auditors.

check_boxKey Events

• Proposed Highly Dilutive Equity Plan

  Shareholders will vote on a plan to immediately increase authorized shares by 2,658,525 (10.0% of current outstanding) and include an evergreen provision for up to 10.0% annual increases for five years (2027-2031).

• Ongoing 'Going Concern' Warning

  The company continues to operate under a 'substantial doubt about its ability to continue as a going concern,' as previously disclosed in its 10-K and noted in its former auditor's report.

• Executive Compensation Details

  The filing reveals executive compensation, including modifications to stock options for the CEO, CFO, and CSO in November 2025, which involved reduced exercise prices.

• Auditor Ratification

  Shareholders will ratify the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for 2026, following the dismissal of Marcum LLP in May 2025.

auto_awesomeAnalysis

Inmune Bio, Inc. is seeking shareholder approval for a Third Amended and Restated 2021 Stock Incentive Plan, which would immediately increase the shares authorized for issuance by 2,658,525 shares, representing 10.0% of current outstanding shares. This plan also includes an evergreen provision allowing for annual increases of up to 10.0% of outstanding shares for five years (2027-2031). This represents a substantial potential for future dilution for a nano-cap company already facing 'substantial doubt about its ability to continue as a going concern,' as noted in its recent 10-K and by its former auditor. While such plans are crucial for incentivizing employees, the magnitude of potential dilution is significant for a company in a precarious financial position. The filing also details executive compensation, including past option modifications with reduced exercise prices for key executives, which is a negative signal. Investors should carefully consider the long-term dilutive impact of this plan.